A. C. Ludolph, J. Brettschneider, and J. H. Weishaupt, Amyotrophic lateral sclerosis, Curr. Opin. Neurol, vol.25, pp.530-535, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00557418

L. Dupuis, P. Pradat, A. C. Ludolph, and J. Loeffler, Energy metabolism in amyotrophic lateral sclerosis, Lancet Neurol, vol.10, pp.75-82, 2011.

R. S. Peter, Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia, Eur. J. Epidemiol, vol.32, pp.901-908, 2017.

G. Nagel, Adipokines, C-reactive protein and Amyotrophic Lateral Sclerosis -results from a population-based ALS registry in Germany, Sci. Rep, vol.7, p.4374, 2017.

S. E. Park, C. Park, and G. Sweeney, Biomarkers of insulin sensitivity and insulin resistance: Past, present and future, Crit. Rev. Clin. Lab. Sci, vol.52, pp.180-190, 2015.

S. Rauskolb, B. Dombert, and M. Sendtner, Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis, Neurobiol. Dis, vol.97, pp.103-113, 2017.

M. E. Lewis, Insulin-like growth factor-I: potential for treatment of motor neuronal disorders, Exp. Neurol, vol.124, pp.73-88, 1993.

I. Torres-aleman, V. Barrios, and J. Berciano, The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis, Neurology, vol.50, pp.772-776, 1998.

K. Maiese, Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease, Neural Regen. Res, vol.10, pp.518-528, 2015.

D. Wen, The role of insulin-like growth factor 1 in ALS cell and mouse models: A mitochondrial protector, Brain Res. Bull, vol.144, pp.1-13, 2018.

G. Dobrowolny, Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model, J. Cell Biol, vol.168, pp.193-199, 2005.

J. C. Dodge, AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice, Mol. Ther, vol.18, pp.2075-2084, 2010.

A. C. Lepore, Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS, Brain Res, vol.1185, pp.256-265, 2007.

S. A. Sakowski, A. D. Schuyler, and E. L. Feldman, Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis, Amyotroph. Lateral Scler, vol.10, pp.63-73, 2009.

G. Nagel, H. Ünal, A. Rosenbohm, A. C. Ludolph, and D. Rothenbacher, Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) -registry Swabia, BMC Neurol, vol.13, p.22, 2013.

H. Uenal, Incidence and Geographical Variation of Amyotrophic Lateral Sclerosis (ALS) in Southern Germany -Completeness of the ALS Registry Swabia, PLoS One, vol.9, p.93932, 2014.

A. Rosenbohm, Epidemiology of amyotrophic lateral sclerosis in Southern Germany, J. Neurol, vol.264, pp.749-757, 2017.

S. Hosback, Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis, Growth Horm. IGF Res, vol.17, pp.472-479, 2007.

M. Beauverd, J. D. Mitchell, J. H. Wokke, and G. D. Borasio, Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease, Cochrane Database Syst. Rev, vol.11, p.2064, 2012.

C. Grunseich, Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial, Lancet Neurol, vol.17, pp.1043-1052, 2018.

A. Fergani, A mutation in the dynein heavy chain gene compensates for energy deficit of mutant SOD1 mice and increases potentially neuroprotective IGF-1, Mol. Neurodegener, vol.6, p.26, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00663663

C. Lunetta, Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients, Muscle Nerve, vol.45, pp.200-208, 2012.

H. Lin, Intramuscular Delivery of scAAV9-hIGF1 Prolongs Survival in the hSOD1G93A ALS Mouse Model via Upregulation of D-Amino Acid Oxidase, Mol. Neurobiol, vol.55, pp.682-695, 2018.

M. L. Messi, H. M. Clark, D. M. Prevette, R. W. Oppenheim, and O. Delbono, The lack of effect of specific overexpression of IGF-1 in the central nervous system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model of ALS, Exp. Neurol, vol.207, pp.52-63, 2007.

S. Doré, S. Kar, and R. Quirion, Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases, Trends Neurosci, vol.20, pp.326-331, 1997.

A. Musarò, K. J. Mccullagh, F. J. Naya, E. N. Olson, and N. Rosenthal, IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1, Nature, vol.400, pp.581-585, 1999.

K. Hua, M. E. Forbes, R. J. Lichtenwalner, W. E. Sonntag, and D. R. Riddle, Adult-onset deficiency in growth hormone and insulinlike growth factor-I alters oligodendrocyte turnover in the corpus callosum, Glia, vol.57, pp.1062-1071, 2009.

F. J. Steyn, Impairments to the GH-IGF-I axis in hSOD1G93A mice give insight into possible mechanisms of GH dysregulation in patients with amyotrophic lateral sclerosis, Endocrinology, vol.153, pp.3735-3746, 2012.

A. Chaudhari, R. Gupta, S. Patel, N. Velingkaar, and R. Kondratov, Cryptochromes regulate IGF-1 production and signaling through control of JAK2-dependent STAT5B phosphorylation, Mol. Biol. Cell, vol.28, pp.834-842, 2017.

A. Breit, Insulin-like growth factor-1 acts as a zeitgeber on hypothalamic circadian clock gene expression via glycogen synthase kinase-3? signaling, J. Biol. Chem, vol.293, pp.17278-17290, 2018.

M. Gorges, Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis, J. Neurol. Neurosurg. Psychiatry, vol.88, pp.1033-1041, 2017.

C. P. Hawkes and A. Grimberg, Insulin-Like Growth Factor-I is a Marker for the Nutritional State, Pediatr. Endocrinol. Rev, vol.13, pp.499-511, 2015.

A. Rosenbohm, Association of Serum Retinol-Binding Protein 4 Concentration With Risk for and Prognosis of Amyotrophic Lateral Sclerosis, JAMA Neurol, vol.75, pp.600-607, 2018.

. Department-of-neurology, C. Schell, and . Kreiskliniken-reutlingen,

K. Schuetz and K. Schwenningen,

W. Sperber and . Kliniken-esslingen,

F. Weber, . Bundeswehrkrankenhaus, A. Winkler, and . Tu-münchen, The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all data in the study and